Latest news

• bluebird bio to separate oncology and rare diseases units

  Oncology Newco will assume responsibility for a number of bluebird bio’s current oncology assets, including its investigational BCMA-targeting CAR T therapy idecabtagene vicleucel (ide-cel), which is currently being

• FDA delays BMS’ liso-cel decision, citing COVID-19 travel restrictions

  BMS also agreed similar conditional payments, dependent on approval, for Celgene’s multiple sclerosis therapy Zeposia (ozanimod) and another CAR-T therapy, ide-cel (idecabtagene vicleucel). ... Zeposia was approved earlier this year, while ide-cel’s

• FDA hands BMS and bluebird bio a priority review for ide-cel

  Myer Squibb and bluebird bio’s submission for their CAR-T immunotherapy ide-cel has finally been accepted by the agency. ... The immunotherapy, idecabtagene vicleucel (ide-cel/bb2121), is designed to treat adult patients with relapsed and refractory

• BMS/bluebird bio resubmit FDA application for myeloma CAR-T

  The immunotherapy, idecabtagene vicleucel (ide-cel/bb2121), is designed to treat adult patients with relapsed and refractory myeloma. ... Among this heavily pre-treated group, ide-cel induced an overall response rate of over 73.4% and a complete

• Bluebird bio pushes back commercial launch of Zynteglo due to COVID-19

  It has, however, suspended enrolment for its Bristol-Myers Squibb-partnered studies for ide-cel, which includes the KarMMa-2, KarMMa-3 and KarMMa-4 studies.